Quick Answer
NextCure, Inc. reported Net Income Loss of -$55.84 million for the year ending 2025.
- NextCure, Inc. showed a decrease of -0.3% in Net Income Loss from 2024 to 2025.
- This data is from NextCure, Inc.'s annual report (Form 10-K), filed with the SEC on March 5, 2026.
- XBRL data for this metric is available from 2018 to 2025 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2018: -$5.00 million | Q2 2018: -$5.23 million | Q3 2018: -$5.71 million | Q1 2019: -$6.16 million | Q2 2019: -$8.22 million | Q3 2019: -$8.43 million | Q1 2020: $9.73 million | Q2 2020: -$14.51 million | Q3 2020: -$16.37 million | Q1 2021: -$16.53 million | Q2 2021: -$17.99 million | Q3 2021: -$17.93 million | Q1 2022: -$20.60 million | Q2 2022: -$17.92 million | Q3 2022: -$18.91 million | Q1 2023: -$16.10 million | Q2 2023: -$17.86 million | Q3 2023: -$14.30 million | Q1 2024: -$17.11 million | Q2 2024: -$15.40 million | Q3 2024: -$11.54 million | Q1 2025: -$10.98 million | Q2 2025: -$26.81 million | Q3 2025: -$8.62 million.
- Over the full 8 years of available data (2018 to 2025), NextCure, Inc.'s Net Income Loss has declined by 144.9%.
- Historical annual values: Fiscal year 2025: -$55.84 million | Fiscal year 2024: -$55.65 million | Fiscal year 2023: -$62.72 million | Fiscal year 2022: -$74.73 million | Fiscal year 2021: -$69.39 million | Fiscal year 2020: -$36.60 million | Fiscal year 2019: -$33.74 million | Fiscal year 2018: -$22.80 million.
- Data sourced from SEC EDGAR public filings as of August 8, 2026.
Last verified: